Workplace testing of drugs of abuse and psychotropic drugs;Exploration biologique des drogues illicites et des médicaments psychotropes en milieu professionnel

Annales Pharmaceutiques Francaises

Volumn 70, Issue 3, 2012, Pages 120-132

  Mura, P ^a   Saussereau, E ^b   Brunet, B ^a   Goulle J P ^b,c  

^a POITIERS UNIVERSITY HOSPITAL   (France)

^b LE HAVRE HOSPITAL   (France)

^c UNIVERSITÉ DE ROUEN   (France)

Author keywords

Drugs; Drugs of abuse; Psychotropics; Quantification; Screening; Workplace

Indexed keywords

PSYCHOTROPIC AGENT;

ANALYTIC METHOD; BLOOD ANALYSIS; BODY FLUID; DRUG ABUSE; DRUG SCREENING; REVIEW; URINALYSIS; WORKPLACE;

AMPHETAMINE-RELATED DISORDERS; CANNABINOIDS; CHRONIC DISEASE; COCAINE-RELATED DISORDERS; FALSE NEGATIVE REACTIONS; FALSE POSITIVE REACTIONS; FRANCE; HUMANS; OPIOID-RELATED DISORDERS; PSYCHOTROPIC DRUGS; REPRODUCIBILITY OF RESULTS; SALIVA; STREET DRUGS; SUBSTANCE ABUSE DETECTION; SUBSTANCE-RELATED DISORDERS; TETRAHYDROCANNABINOL; WORKPLACE;

EID: 84861664706     PISSN: 00034509     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.pharma.2012.03.002     Document Type: Review

References (84)

1. Consommation de drogues illicites en milieu professionnel : état des lieux des connaissances et des recherches menées en France, note no 2010-9, 14 juin 2010, observatoire français des drogues et toxicomanies.
2. Lhermitte, Haguenoer (ce numéro) à compléter par l'éditeur.
3. Ordonnance no 2010-49 du 13 janvier 2010 relative à la biologie médicale. JO no 12 du 15 janvier 2010, page 819.
4. Mura P. Accidentologie et drogues illicites. Bull Acad Natl Med 2002, 186:345-357.
5. Beck O., Sandqvist S., Dubbelboer I., Franck J. Detection of delta-9-tetrahydrocannabinol in exhaled breath collected from cannabis users. J Anal Toxicol 2011, 35(8):541-544.
6. Beck O., Leine K., Palmskog G., Franck J. Amphetamines detected in exhaled breath from drug addicts: a new possible method for drugs of abuse testing. J Anal Toxicol 2010, 34(5):233-237.
7. Mura P, Kintz P. Drogues et accidentalité. Chapitre : dépistage urinaire. Cirimele V, Pelissier-Alicot AL. EDP Sciences 2011.
8. Cone E.J., Lange R., Darwin W.D. In vivo adulteration: excess fluid causes false-negative marijuana and cocaine urine test results. J Anal Toxicol 1998, 22:460-473.
9. Dasgupta A., Chugtai O., Hannah C., Davis B., Wells A. Comparison of spot tests with AdultaCheck 6 and Intect 7 urine tests strips for detecting the presence of adulterants in urine specimens. Clin Chim Acta 2004, 348:19-25.
10. Dumestre-Toulet V. Passer à travers les tests de dépistage : substitution, dilution, adultération des urines et des cheveux. Ann Toxicol Anal 2002, 14:43-49.
11. Mura P, Kintz P. Drogues et accidentalité. Chapitre : le dépistage salivaire. Verstraete A. EDP Sciences 2011.
12. Mura P, Kintz P. Drogues et accidentalité. Chapitre : aspects légaux et réglementaires en France et en Europe. Arditti J, Vertsraete A, Kuhlmann. EDP Sciences 2011.
13. Krasowski M.D., Siam M.G., Lyer M., Pizon A.F., Giannoutsos S., Ekins S. Chemoinformatic methods for predicting interference in drug of abuse/toxicology immunoassays. Clin Chem 2009, 55:1203-1213.
14. Mura P., Kintz P., Papet Y., Ruestch G. évaluation de six tests rapides pour le dépistage du cannabis dans la sueur, la salive et les urines : corrélation avec la GC-MS. Acta Clin Belg 1999, 1:35-38.
15. Cirimele V., Villain M., Mura P., Bernard M., Kintz P. Oral fluid testing for cannabis: on-site Oraline IV s.a.t. device versus GC/MS. Forensic Sci Int 2006, 161:180-184.
16. Mura P., Papet Y., Brunet B. Intérêt du triage TOX drug screen pour le dépistage urinaire de drogues illicites et de médicaments. Ann Toxicol Anal 2007, 19:221-225.
17. Kintz P., Brunet B., Muller J.F., Serra W., Villain M., Mura P. Evaluation of the Cozart DDSV test for cannabis in oral fluid. Ther Drug Monit 2009, 31:131-134.
18. Wille S.M., Samyn N., Ramirez-Fernandez Mdel M., De Boeck G. Evaluation of on-site oral fluid screening using Drugwipe-5(+), RapidSTAT and Drug Test 5000 for the detection of drugs of abuse in drivers. Forensic Sci Int 2010, 198:2-6.
19. Röhrich J., Zörntlein S., Becker J., Urban R. Detection of delta-9-tetrahydrocannabinol and amphetamine-type stimulants in oral fluid using the Rapid Stat point-of-collection drug-testing device. J Anal Toxicol 2010, 34(3):155-161.
20. Pehrsson A., Blencowe T., Vimpari K., Langel K., Engblom C., Lillsunde P. An evaluation of on-site oral fluid drug screening devices DrugWipe5+ and Rapid STAT using oral fluid for confirmation analysis. J Anal Toxicol 2011, 35(4):211-218.
21. Blencowe T., Pehrsson A., Lillsunde P., Vimpari K., Houwing S., Smink B., et al. An analytical evaluation of eight on-site drug screening devices using laboratory confirmation results from oral fluid. Forensic Sci Int 2011, 208:173-179.
22. ®. Ann Biol Clin 2002, 60:745-746.
23. Delacour H., Servonnet A., Gardet V. Dépistage du cannabis dans les urines : attention à l'acide niflumique. Ann Toxicol Anal 2005, 17:203-206.
24. Reidy L., Walls H.C., Steele B.W. Crossreactivity of bupropion metabolite with enzyme-linked immunosorbent assays designed to detect amphetamine in urine. Ther Drug Monit 2011, 33(3):366-368.
25. Gilbert R.B., Peng P.I., Wong D. A labetolol metabolite with analytical characteristics resembling amphetamines. J Anal Toxicol 1995, 19:84-86.
26. Yee L.M., Wu D. False-positive amphetamine toxicology screen results in three pregnant women using labetalol. Obstet Gynecol 2011, 117:503-506.
27. Baden L.R., Horowitz G., Jacoby H., Eliopoulos G.M. Quinolones and false-positive urine screening for opiates by immunoassay technology. JAMA 2001, 286:3115-3119.
28. Zacher J.L., Givone D.M. False-positive urine opiate screening associated with fluoroquinolone use. Ann Pharmacother 2004, 38(9):1525-1528.
29. Mura P, Kintz P. Drogues et accidentalité. Chapitre : réponses aux questions les plus souvent posées. Mura P. EDP Sciences 2011.
30. Elsohly M.A., Jones A.B. Drug-testing in the workplace: could a positive test for one of the mandated drugs be for reasons other than illicit use of the drug. J Anal Toxicol 1995, 19:50-58.
31. Rohrig T.P., Moore C. The determination of morphine in urine and oral fluid following ingestion of poppy seeds. J Anal Toxicol 2003, 27:449-452.
32. Jankovicova K., Ulbrich P., Fukova M. Effect of poppy seed consummation on the positive results of opiates screening in biological samples. Leg Med 2009, 11:416-418.
33. Giroud C., Menetrey A., Augsburger M., et al. Delta(9) - THC, 11-OH-Delta (9) -THC and Delta (9)-THCCOOH plasma or serum to whole blood concentrations distribution ratios in blood samples taken from living and dead people. Forensic Sci Int 2001, 123:159-164.
34. Kintz P., Cirimèle V., Pépin G., Marquet P., Deveaux M., Mura P. Identification et dosage des cannabinoïdes dans le sang total. Toxicorama 1996, 8(2):29-33.
35. Goullé JP, Paschal L, Lesieur M, Danger P, Lacroix C. Application de la GC-MS/MS à la technique de dosage des cannabinoïdes sanguins recommandée par la SFTA. 13ème Congrès de la Société Française de Toxicologie Analytique. Pau, 8-10 juin 2005. Ann Toxicol Anal. 2005; 17(3):169 [Résumé].
36. Mura P, Kintz P. Drogues et accidentalité. Chapitre : dosages sanguins et urinaires. Saussereau E, Goullé J.P., Lacroix C, Ricordel I. EDP Sciences 2011.
37. Goullé J.P., Saussereau E., Lacroix C. Pharmacocinétique du delta-9-tétrahydrocannabinol (THC). Ann Pharm Fr 2008, 66:232-244.
38. Harvey D.J. Absorption, distribution and biotransformation of the cannabinnoids. Marihuana and medicine 1999, 91-103. Humana press, Totowa, New Jersey. G.G. Nahas, K.M. Sutin, D. Harvzy, S. Agurell (Eds.).
39. Huestis M., Henningfield J.E., Cone E.J. Blood cannabinoids. I. Absorption of THC and formation of 11-OH-THC and THC-COOH during and after smoking marijuana. J Anal Toxicol 1992, 16:276-282.
40. Kauert G.F., Ramaekers G., Schneider E., Moeller M.R., Toennes S.W. Pharmacokinetic properties of delta9-tetrahydrocannabinol in serum and oral fluid. J Anal Toxicol 2007, 31:288-293.
41. Huestis M.A., Henningfield J.E., Cone E.J. Blood cannabinoids. II. Models for the prediction of time of marijuana exposure from plasma concentrations of 9-tetrahydrocannabinol (THCCOOH). J Anal Toxicol 1992, 16:283-290.
42. Daldrup T. Cannabis im Strassenverkehr Avschlussbericht des im Auftrage des Ministeriums für Wirtschaft und mittelstand Technologie und Verkenhr des Landes Nordrhein-Westfalen durchgeführten untersuchungsvorhabens. 1996; 44-59.
43. Huestis M.A., Mitchell J.M., Cone E.J. Urinary exception profiles of 11-nor-9-carboxy-delta 9-tetrahydrocannabinol in humans after single smoked dose of marijuana. J Anal Toxicol 1996, 20:441-452.
44. Smith-Kielland A., Skuterud B., Morland J. Urinary excretion of 11-nor-carboxy-delta 9-tetrahydrocannabinol and cannabinoïdes and in frequent and infrequent drug users. J Anal Toxicol 1999, 23:323-332.
45. Reiter A., Hake J., Meissner C., Rohwer J., Friedrich H.U., Oehmichen M. Time of drug elimination in chronic drug abusers. Case study of 52 patients in a low-step detoxication ward. Forensic Sci Int 2001, 119:248-253.
46. Barnett G., Licko V., Thompson T. Behavioral pharmacokinetics of marijuana. Psychopharmacology 1985, 85:51-56.
47. Harder S., Rietbrock S. Concentration-effect relationship of delta-9-tetrahydrocannabiol and prediction of psychotropic effects after smoking marijuana. Int J Clin Pharmacol Ther 1997, 35:155-159.
48. Ohlsson A., Lindren J.E., Wahlen A., Agurell S., Hollister L.E., Gillespie H.K. Plasma delta-9-tetrahydrocannabinol concentrations and clinical effects after oral and intravenous administration and smoking. Clin Pharmacol Ther 1980, 28:409-416.
49. Cone E.J., Huestis M.A. Relating blood concentrations of tétrahydrocannabinol and metabolites to pharmacologic effects and time of marijuana usage. Ther Drug Monit 1993, 15:527-532.
50. Mura P., Kintz P., Ludes B., Gaulier J.M., Marquet P., Martin-Dupont S., et al. Comparison of the prevalence of alcohol, cannabis and other drugs between 900 injured drivers and 900 control subject: results of a French collaborative study. Forensic Sci Int 2003, 133:79-85.
51. McBay A.J. Drug concentrations and traffic safety. Alcohol Drugs Driving 1986, 2:51-59.
52. Mura P., Kintz P., Dumestre V., Raul S., Hauet T. THC can be detected in brain while absent in blood. J Anal Toxicol 2005, 29:692-693.
53. Ragoucy Senger C. Cocaïne in toxicology et pharmacology médicolégales. 1998, 431-463. Elsevier Option Bio, Paris. P. Kintz (Ed.).
54. Jones A.W., Holmgree A., Kugelberg F.C. Concentrations of cocaine and its major metabolite benzoylecgonine in blood samples from apprehended drivers in Sweden. Forensic Sci Int 2008, 177:133-139.
55. Gaillard Y., Pépin G., Marquet P., Kintz P., Deveaux M., Mura P. Identification et dosage de la benzoylecgonine, cocaïne, méthylecgonine-ester, codéine, morphine et 6-acétylmorphine dans le sang total. Toxicorama 1999, 8(2):17-22.
56. Commission contrôle de qualité de la société française de toxicologie analytique. http://www.%20sfta.org/.
57. Jeanville P.M., Estapé E.S., Torres-Negron I., Marti A. Rapid confirmation/quantitation of ecgonine methyl ester, benzoylecgonine, and cocaine in urine using on-line extraction coupled with fast HPLC and tandem mass spectrometry. J Anal Toxicol 2001, 25(1):69-75.
58. Lacroix C., Saussereau E., Bodin G., Goullé J.P. Quantification des opiacés, cocaïniques et amphétaminiques par chromatographie liquide haute performance/spectrométrie de masse en tandem après préparation en ligne de l'échantillon. Ann Toxicol Anal 2008, 20(1):25-38.
59. Huestis M.A., Darwin W.D., Shimomura E., Lalani S.A., Trinidat D.V., Jenkins A.J., et al. Cocaine metabolites urinary excretion after controlled smoked administration. J Anal Toxicol 2007, 31:462-468.
60. Bengtsson J., Jansson B., Hanmarlund-Udenaes M. On-line desalting and determination of morpnine, morphine-3-glucuronide and morphine-6-glucuronide in microdialysis and plasma samples using column switching and liquid chromatography tandem mass spectrometry. Rapid Commun Mass Spectrom 2005, 19(15):2116-2122.
61. Thörngren J.O., östervall F., Garle M. A high-througput multicomponent screening method for diuretic, masking agents, central nervous system (CNS) stimulants and opiates in human urine by UPLC-MS/MS. J Mass Spectrom 2008, 43(7):980-992.
62. Rifflet A, Richeval C, Humbert L, Orkild AM, Legeleux O, Lhermitte M. Analyse ultrarapide des dérivés amphétaminiques, des opiacés, de la cocaïne et ses métabolites par UPLC-MS/MS après une simple extraction SPE dans du sang total. SFTA, juin 2006, Le Touquet, France.
63. Trescot A.M., Datta S., Lee M., Hansen H. Opioid pharmacology. Pain Physician 2008, 11(Suppl. 2):5133-5153.
64. Ceder G., Jones A.W. Concentration ratios of morphine to codeine in blood of impaired drivers as evidence of heroin use and not medication with codeine. Clin Chem 2001, 47(11):1980-1984.
65. Smith M.L., Shimomura E.T., Summers J., Paul B.D., Jenkins A.J., Darwin W.D. Urinary excretion profiles for total morphine, free morphine, and 6-acetylmorphine following smoked and intravenous heroin. J Anal Toxicol 2001, 25(7):504-514.
66. Baselt RC. Disposition of toxics drugs on chemicals in human. Biomedical publications, 2008, 8ème edition.
67. Marquet P., Lachâtre G., Kintz P., Pépin G., Deveaux M. Identification et dosage des principales drogues amphétaminiques dans le sang total par chromatographie en phase gazeuse couplée à la spectrométrie de masse. Toxicorama 1996, 8(2):23-28.
68. Huestis M.A., Cone E.J. Methamphetamine disposition in oral fluid, plasma, and urine. Ann N Y Acad Sci 2007, 1098:104-124.
69. Kintz P., Mangin P. Expertises judiciaires à partir d'échantillons de cheveux. J Med Leg Droit Med 1995, 38:241-244.
70. Goullé J.P., Kintz P. Un nouveau moyen d'investigation biologique : l'analyse des cheveux. Intérêt en pratique médicale. Rev Med Interne 1996, 17:826-835.
71. o 2003-293 du 31 mars 2003. Restitution de permis de conduire à partir d'analyses de cheveux. Ann Toxicol Anal 2003, 15:117-122.
72. Goullé J.P., Kintz P., Lafargue P., Lardet G., Molinaro G., Pépin G., et al. Consensus sur l'analyse des substances organiques dans les cheveux. Toxicorama 1994, 6:5-8.
73. Taylor E.H., Pizzo P. Evaluation of the DrugCheck 9 on-site immunoassay test cup according to a standard method validation protocol. J Anal Toxicol 2004, 28(3):190-197.
74. Attema-de Jonge M.E., Peeters S.Y., Franssen E.J. Performance of three point-of-care urinalysis test devices for drugs of abuse and therapeutic drugs applied in the emergency department. J Emerg Med 2011, [Epub ahead of print].
75. Mura P., Barritault N., Jehl E., Kintz P. Evaluation du triage 8 pour le dépistage des stupéfiants et médicaments psychotropes dans les urines de 163 conducteurs impliqués dans un accident corporel et de 33 patients toxicomanes. Ann Toxicol Annal 2001, 13:150-151.
76. Grönholm M., Lillsunde P. A comparison between on-site immunoassay drug-testing devices and laboratory results. Forensic Sci Int 2001, 121:37-46.
77. Mura P., Kintz P., Robert R., Papet Y. Buflomedil is a potent interfering substance in immunoassays of tricyclic antidepressants. J Anal Toxicol 1998, 22:254.
78. Verstraete A.G. Oral fluid testing for driving under the influence of drugs: history, recent progress and remaining challenges. Forensic Sci Int 2005, 150:143-150.
79. Pehrsson A., Gunnar T., Engblom C., Seppä H., Jama A., Lillsunde P. Roadside oral fluid testing: comparison of the results of drugwipe 5 and drugwipe benzodiazepines on-site tests with laboratory confirmation results of oral fluid and whole blood. Forensic Sci Int 2008, 175:140-148.
80. Lesser A.J. Phenylketonuria and the Guthrie test. Pediatrics 1963, 32:940.
81. Saussereau E, Lacroix C, Goullé JP. Dosage des opiacés, amphétamines et cocaïniques à partir de spots de sang par LC-MS/MS couplée à une préparation en ligne des échantillons. Congrès de la Société Française de Toxicologie Analytique, Antibes, 9-10 juin 2010.
82. Lacroix C., Wojciechowski F., Danger P. Monitoring of benzodiazepines (clobazam, diazepam and their main active metabolites) in human plasma by coloumn-switching high-performance liquid chromatography. J Chromatogr 1993, 617:285-290.
83. Mallet C.R., Mazzeo J., Neue U. Evalution of several solid phase extraction liquid chromatography/tandem mass spectrometry on-line configuration for high-troughput analysis of acidic and basic drugs in rat plasma. Rapid Commun Mass Spectrom 2001, 15:1075-1083.
84. Jemal M. High-troughput quantitative bioanalysis by LC/MS/MS. Biomed Chromatogr 2000, 14:422-429.